MX2015006931A - Terapia combinada para tratar cánceres her2-positivos. - Google Patents
Terapia combinada para tratar cánceres her2-positivos.Info
- Publication number
- MX2015006931A MX2015006931A MX2015006931A MX2015006931A MX2015006931A MX 2015006931 A MX2015006931 A MX 2015006931A MX 2015006931 A MX2015006931 A MX 2015006931A MX 2015006931 A MX2015006931 A MX 2015006931A MX 2015006931 A MX2015006931 A MX 2015006931A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapy
- positive cancers
- treating her2
- her2
- her2 antibody
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/16—Holders for containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732736P | 2012-12-03 | 2012-12-03 | |
| US201361810254P | 2013-04-09 | 2013-04-09 | |
| PCT/US2013/072941 WO2014089127A1 (en) | 2012-12-03 | 2013-12-03 | Combination therapy for treating her2-positive cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015006931A true MX2015006931A (es) | 2016-07-05 |
Family
ID=50883946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015006931A MX2015006931A (es) | 2012-12-03 | 2013-12-03 | Terapia combinada para tratar cánceres her2-positivos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9913901B2 (enExample) |
| EP (1) | EP2925361A4 (enExample) |
| JP (1) | JP2016501234A (enExample) |
| KR (1) | KR20150091116A (enExample) |
| CN (2) | CN105050619A (enExample) |
| AU (1) | AU2013355337B2 (enExample) |
| CA (1) | CA2892859A1 (enExample) |
| HK (1) | HK1214955A1 (enExample) |
| IL (1) | IL239031A0 (enExample) |
| MX (1) | MX2015006931A (enExample) |
| SG (1) | SG11201504293WA (enExample) |
| WO (1) | WO2014089127A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015006931A (es) | 2012-12-03 | 2016-07-05 | Merrimack Pharmaceuticals Inc | Terapia combinada para tratar cánceres her2-positivos. |
| AU2014290044B2 (en) * | 2013-07-17 | 2020-10-29 | Foundation Medicine, Inc. | Methods of treating urothelial carcinomas |
| US20160045596A1 (en) * | 2014-08-05 | 2016-02-18 | Merrimack Pharmaceuticals, Inc. | Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies |
| WO2017136770A1 (en) * | 2016-02-05 | 2017-08-10 | Merrimack Pharmaceuticals, Inc. | Treatment of her2-intermediate cancer |
| WO2018127791A2 (en) | 2017-01-06 | 2018-07-12 | Biosion, Inc. | Erbb2 antibodies and uses therefore |
| CN115957321A (zh) * | 2023-03-03 | 2023-04-14 | 盛禾(中国)生物制药有限公司 | 一种抗her2抗体在制备治疗癌症的药物中的用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US20050084524A1 (en) * | 1998-09-30 | 2005-04-21 | Alza Corporation | Method for potentiating activity of a chemotherapeutic drug |
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| GB0326486D0 (en) | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| US7674456B2 (en) | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
| TWI441646B (zh) * | 2005-01-21 | 2014-06-21 | Genentech Inc | 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途 |
| EP1871424A2 (en) | 2005-04-22 | 2008-01-02 | Alza Corporation | Immunoliposome composition for targeting to a her2 cell receptor |
| CN101355928B (zh) * | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| AU2008303466A1 (en) | 2007-09-28 | 2009-04-02 | Universitatsspital Basel | Immunoliposomes for treatment of cancer |
| CN102057054B (zh) | 2008-04-11 | 2015-06-10 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| KR20140041396A (ko) * | 2010-12-06 | 2014-04-04 | 메리맥 파마슈티컬즈, 인크. | 안트라사이클린 화학요법제를 포함하는 erbb2-표적 면역리포좀으로의 치료에서 심장독성을 예방하기 위한 용량 및 투여 |
| US20120231066A1 (en) | 2011-01-24 | 2012-09-13 | Henry John Smith | Multi-drug liposomes to treat tumors |
| MX2015006931A (es) | 2012-12-03 | 2016-07-05 | Merrimack Pharmaceuticals Inc | Terapia combinada para tratar cánceres her2-positivos. |
-
2013
- 2013-12-03 MX MX2015006931A patent/MX2015006931A/es unknown
- 2013-12-03 US US14/650,250 patent/US9913901B2/en not_active Expired - Fee Related
- 2013-12-03 KR KR1020157017006A patent/KR20150091116A/ko not_active Withdrawn
- 2013-12-03 CN CN201380070261.4A patent/CN105050619A/zh active Pending
- 2013-12-03 HK HK16102942.7A patent/HK1214955A1/zh unknown
- 2013-12-03 SG SG11201504293WA patent/SG11201504293WA/en unknown
- 2013-12-03 CA CA2892859A patent/CA2892859A1/en not_active Abandoned
- 2013-12-03 CN CN201710112540.2A patent/CN107412163A/zh active Pending
- 2013-12-03 WO PCT/US2013/072941 patent/WO2014089127A1/en not_active Ceased
- 2013-12-03 AU AU2013355337A patent/AU2013355337B2/en not_active Expired - Fee Related
- 2013-12-03 EP EP13860427.7A patent/EP2925361A4/en not_active Withdrawn
- 2013-12-03 JP JP2015545523A patent/JP2016501234A/ja active Pending
-
2015
- 2015-05-27 IL IL239031A patent/IL239031A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150091116A (ko) | 2015-08-07 |
| CN105050619A (zh) | 2015-11-11 |
| AU2013355337A1 (en) | 2015-07-09 |
| EP2925361A4 (en) | 2016-06-29 |
| WO2014089127A1 (en) | 2014-06-12 |
| US9913901B2 (en) | 2018-03-13 |
| IL239031A0 (en) | 2015-07-30 |
| AU2013355337B2 (en) | 2018-07-12 |
| SG11201504293WA (en) | 2015-06-29 |
| EP2925361A1 (en) | 2015-10-07 |
| CN107412163A (zh) | 2017-12-01 |
| HK1214955A1 (zh) | 2016-08-12 |
| JP2016501234A (ja) | 2016-01-18 |
| US20160250328A1 (en) | 2016-09-01 |
| CA2892859A1 (en) | 2014-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015006931A (es) | Terapia combinada para tratar cánceres her2-positivos. | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| NZ719368A (en) | Combination therapy of antibodies against human csf-1r and uses thereof | |
| MX349198B (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| EP3606964A4 (en) | SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY | |
| BR112015023910A2 (pt) | terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer | |
| IN2015KN00350A (enExample) | ||
| CL2016002359A1 (es) | Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco | |
| PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
| HK1258921A1 (zh) | Flt3 定向 car 细胞免疫疗法 | |
| NZ716473A (en) | Diagnosis and therapy of cancer involving cancer stem cells | |
| WO2016051398A8 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| PH12020551715A1 (en) | Methods of treating cancer | |
| MX2020001727A (es) | Terapia de combinacion. | |
| PH12014501543A1 (en) | Combination therapy for the treatment of ovarian cancer | |
| MX2016001541A (es) | Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos. | |
| MX2015015434A (es) | Corroles dirigidas para toxicidad tumoral y rm. | |
| MX2014013763A (es) | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. | |
| MX2022006155A (es) | Terapias anticancerosas con anamicina liposomica orientadas al pulmon. | |
| NZ701974A (en) | Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation | |
| MX2015004703A (es) | Composiciones cancerigenas inyectables. | |
| WO2018231799A8 (en) | Methods of treating brain tumors using combination therapy | |
| MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. |